Sign In
Buy PVCT
$0.0651
-0.0029 (-4.34%)
At Close: Jul 13, 2026
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
08:00am, Tuesday, 07'th Jul 2026
Peer-reviewed preclinical melanoma research finds Provectus's synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose. A recently publishe
KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceu
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
08:00am, Thursday, 25'th Jun 2026
Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials. Veripure is also a quality benchmark, distinguis
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
10:02pm, Thursday, 18'th Jun 2026
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
08:00am, Monday, 08'th Jun 2026
KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (th
Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,
New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn. , May 04,
KNOXVILLE, Tenn., May 04, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biopharmaceutical company developing propri
KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will hold its 2026 Annual Meeting o
KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical r
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December
01:40am, Tuesday, 13'th Jan 2026
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 801,17
KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical r
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
08:00am, Monday, 29'th Sep 2025
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lea
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
08:00am, Thursday, 26'th Jun 2025
KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by C
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
08:00am, Monday, 09'th Jun 2025
KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (th
